csirt@kutim:~/threat-intel/cve/CVE-2026-39970

Katalog CVE

CVSS 8.5 · High EPSS 0,40%

Kerentanan Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting'). Skor CVSS 4.0 8.5 (High) menurut github.com.

Deskripsi (NVD)

TypeBot is a chatbot builder tool. Versions 3.15.2 and prior contain a critical stored XSS vulnerability in the app.typebot.io profile picture upload form. The application fails to sanitize or restrict SVG/XML-based uploads and directly renders them when accessed through the domain. By uploading a crafted malicious SVG file containing embedded JavaScript, an attacker will execute arbitrary JavaScript code. This vulnerability directly enables stored XSS exploitation because the payload is persistently stored on your infrastructure (app.typebot.io) and accessible from a public-facing, permanent link. Stored XSS via malicious SVG uploads to app.typebot.io allows attackers to execute arbitrary JavaScript in victims' browsers, enabling session/token theft, account takeover, and exfiltration of sensitive user data. This issue has been fixed in version 3.16.0.

Rincian

Terbit di NVD
22 Mei 2026
Terakhir diubah
23 Juli 2026
Status NVD
Deferred
CVSS 4.0
8.5 (High), sumber github.com
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:P/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-79: Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting')
EPSS (30 hari)
0,40% peluang dieksploitasi; lebih tinggi dari 32,9% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.